# Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE

> **NCT01702038** · PHASE2 · WITHDRAWN · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)**

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01702038
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01702038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01702038, "Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01702038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*